ImmuPharma collaborates with the Centre National de la Recherche Scientifique (CNRS) in France, accessing innovative research at a low cost. They have exclusive rights to their intellectual property assets. Their pipeline includes peptide-based therapeutics for Autoimmunity & Inflammation, Anti-Infectives, Metabolism, and Cancer. Their lead drug candidate, Lupuzor, addresses lupus, a life-threatening autoimmune disease.